Back to search

Article

VHL Expression Level in the Pathological Tissue is Significantly Associated with Hematotoxicity of Platinum-based Chemotherapy in Non-Small Cell Lung Cancer Patients.

2021-07-26

Abstract excerpt

<h4>Objective: </h4> To investigate the association between expression level of Von Hippel-Lindau(VHL) in pathological tissue and hematotoxicity of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. <h4>Methods: </h4> The pathological samples of NSCLC patients were obtained for immunohistochemical staining to evaluate the expression level of VHL. Furthermore, their clinical data were colle...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
87a74b28-b67c-5baf-a4e7-940f1f904848
DOI
10.21203/rs.3.rs-732169/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
VHL Expression Level in the Pathological Tissue is Significantly Associated with Hematotoxicity of Platinum-based Chemotherapy in Non-Small Cell Lung Cancer Patients.DOI 10.21203/rs.3.rs-732169/v1
VHL Expression Level in the Pathological Tissue is Significantly Associated with Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients.Semantic proximity
Albumin Paclitaxel Plus Platinum With or Without Pembrolizumab for Metastatic Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Retrospective Multicenter StudySemantic proximity
DNA damage and repair (DDR) gene mutation profiles in driver gene wild-type advanced non-small cell lung cancer and the predictive role of response to platinum-based chemotherapySemantic proximity
Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients.Semantic proximity
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.Semantic proximity
Impact of GTF2H1 and RAD54L2 gene polymorphisms on the non-small cell lung cancer with Platinum chemotherapy in high altitude areasSemantic proximity
Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study.Semantic proximity
The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.Semantic proximity
Incidence, risk factors, and outcome of advanced NSCLC patients receiving antiangiogenic therapy with thromboembolic events: a retrospective cohort studySemantic proximity
The safety and efficacy of nedaplatin and lobaplatin combined with pemetrexed in first-line chemotherapy for locally advanced and advanced lung adenocarcinoma - A retrospective studySemantic proximity
Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.Semantic proximity
Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.Semantic proximity
Select a neighboring publication to make it the new centre.